By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Orchid Cellmark today announced the two-year extension of contracts previously awarded under the North West/South West and Wales regional forensic tender process in the UK.

The contracts, originally awarded in April 2008, were set to expire in 2011 and have been extended to 2013. In total, the contracts have a value of about $10 million, the company said in a statement.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

A research duo estimates in PLOS One the number of papers that have used misidentified cell lines.

UK's National Institute for Health and Care Excellence approves GlaxoSmithKline's SCID gene therapy despite cost.

Science reports that Brazilian researchers are petitioning for the reversal of budget cuts.

In PLOS this week: gene flow patterns in common ash, guidelines for using morpholinos in zebrafish, and more.